Compare Pfizer Inc (PFE) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Nuscale Power Corporation — how do they compare? Pfizer Inc trades at $28.28 (market cap $158.56B), while Nuscale Power Corporation trades at $7.2 (market cap $3.00B). The key difference: Pfizer Inc is far larger — about 52.9× Nuscale Power Corporation's market cap, and Pfizer Inc pays a 6.18% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Nuscale Power Corporation for 29 Days on average.
| PFE | SMR | |
|---|---|---|
Market Cap | $158.56B | $3.00B |
Volume | 44,138,282 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $29.02 | $53.43 |
52-Week Low | $23.67 | $7.32 |
Typical Hold Time | 158 Days | 29 Days |
Enterprise Value | $210.06B | $1.93B |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
NuScale Power (SMR) trades at $7.32, down 4.56% today, amid bearish technical signals and challenging fundamentals. The company reported significant losses with a net income margin of -3,888.7% in 2026 and negative cash flow from operations. Despite analyst consensus pointing to a $11.25 price target with 50% buy ratings, recent news highlights investor concerns including an ongoing legal investigation announced by Pomerantz Law Firm on October 1, 2026.
The stock faces substantial execution risks as it burns cash to commercialize small modular reactor technology. While nuclear energy presents long-term growth potential, SMR's path to profitability remains uncertain given current financial metrics and competitive pressures from established players like GE Vernova. The wide analyst target range ($6-$16) reflects divided sentiment on the company's prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
